IP Library › Granted Patent US 10,300,173
Granted Patent B2
US 10,300,173 · App. 15/586,443 · Granted May 28, 2019

Compounds and methods for biofilm disruption and prevention

Inventors: James Grant Burgess (Newcastle Upon Tyne, GB); Michael John Hall (Newcastle Upon Tyne, GB); Reindert Nijland (Utrecht, NL)
Assignee: University of Newcastle Upon Tyne
A61L29/16A61K38/465A61K45/06C12N9/22C12Y301/31001A61L2300/252A61L2300/30A61L2300/404A61L2300/45C12Y301/27002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,300,173
App. No.
15/586,443
Granted
May 28, 2019
Kind
B2
Abstract

The invention relates to compounds, compositions and methods for biofilm disruption and prevention. In particular, the invention relates to pharmaceutical compositions for the disruption of biofilm and prevention of biofilm in patients. The invention also relates to anti-biofouling compositions for the disruption of biofilm and prevention of biofilm on surfaces. The invention also relates to the removal of biological material from surfaces. The compositions of the invention include microbial deoxyribonucleases.

Claims (42)

1. A pharmaceutical or anti-biofouling composition for disrupting a biofilm or preventing biofilm formation comprising an isolated microbial deoxyribonuclease polypeptide and an excipient, wherein said composition is coated on at least a portion of a patient-contactable surface of an indwelling medical device, and wherein the microbial deoxyribonuclease is as set forth in SEQ ID NO. 4.

2. The composition of claim 1 further comprising an antimicrobial compound.

3. The composition of claim 2 wherein the antimicrobial compound is an antiparasitic compound which is one or more of a benzazole; a macrocycle; pyrantel pamoate; diethylcarbamazine; niclosamide; praziquantel; melarsoprol; and eflornithine.

4. The composition of claim 2 wherein the antimicrobial compound is an antiviral compound which is one or more of a nucleoside analog reverse transcriptase inhibitor; an uncoating inhibitor; a protease inhibitor; zanamivir; oseltamivir; and rifampin.

5. The composition of claim 2 wherein the antimicrobial compound is an antibacterial compound which is one or more of an aminoglycoside; a beta-lactam; a cephalosporin; a quinolone; a macrolide; an oxazolidinone; an ansamycin; a sulphonamide; a tetracycline; a glycopeptide; sulfisoxazole, trimethoprim, novobiocin, daptomycin and linezolid.

6. The composition of claim 2 wherein the antimicrobial compound is an antifungal compound which is one or more of an azole, a macrocycle, an allyl amine, an echinocandin, polygodial, ciclopyrox, tolnaftate, benzoic acid, undecylenic acid, flucytosine and griseofulvin.

7. The composition of claim 2 wherein the composition is an anti-biofouling composition and the antimicrobial compound is an antibacterial compound which is a parahydroxy benzoic acid ester (parabens).

8. A method of preventing or disrupting a biofilm on a surface comprising contacting the surface with an effective dose of the composition of claim 1 , wherein the surface is at least a portion of a patient-contactable surface of an indwelling medical device.

9. The method of claim 8 wherein said surface is a surface of a catheter.

10. The method of claim 8 wherein the microbial deoxyribonuclease of said composition is attached to said surface.

11. The composition of claim 1 wherein said device is a catheter.

12. A method of preventing or disrupting a biofilm on a surface comprising:

expressing a microbial deoxyribonuclease polypeptide from an expression vector that comprises a polynucleotide encoding the microbial deoxyribonuclease; and

contacting the surface with an effective dose of the microbial deoxyribonuclease polypeptide, wherein the surface is at least a portion of a patient-contactable surface of an indwelling medical device, wherein the microbial deoxyribonuclease is as set forth in SEQ ID NO: 4.

13. The composition of claim 1 wherein said composition is attached to said at least a portion of the patient-contactable surface of said device.

14. The composition of claim 2 wherein said antimicrobial compound is an antibacterial compound, an antiparasitic compound, an antifungal compound or an antiviral compound.

15. The composition of claim 3 wherein:

said benzazole is albendazole, mebendazole or tiabendazole; or

said azole is metronidazole or tinidazole; or

said macrocycle is amphotericin B, rifampin or ivermectin.

16. The composition of claim 4 wherein:

said nucleoside analog reverse transcriptase inhibitor is acyclovir, didanosine, stavudine, zidovudine, lamivudine, abacavir, emtricitabine or entecavir; or

said uncoating inhibitor is amantadine, rimantadine or pleconaril; or

said protease inhibitor is saquinavir, ritonavir, indinavir, nelfinavir or amprenavir.

17. The composition of claim 5 wherein:

said aminoglycoside is gentamicin, kanamycin or streptomycin; or

said beta-lactam is penicillin, ampicillin or imipenem; or

said cephalosporin is ceftazidime, or

said quinolone is ciprofloxacin; or

said macrolide is azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin or telithromycin; or

said oxazolidinone is linezolid; or

said ansamycin is rifamycin; or

said tetracycline is doxycycline; or

said glycopeptide is vancomycin.

18. The composition of claim 6 wherein:

said azole is miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, sertaconazole, sulconazole, tioconazole, fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole or abafungin; or

said macrocycle is natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin or hamycin; or

said allyl amine is terbinafine, naftifine or butenafine; or

said echinocandin is andidulafungin, caspofungin or micafungin.

19. The composition of claim 7 wherein said parahydroxy benzoic acid ester is methyl-paraben, ethyl-paraben, propyl-paraben, butyl-paraben or benzyl-paraben.

20. The method of claim 8 wherein said surface is a surface of a central venous catheter, intravascular catheter, urinary catheter, Hickman catheter, peritoneal dialysis catheter, endrotracheal catheter, or the surface of a mechanical heart valve, a cardiac pacemaker, an arteriovenous shunt, a schleral buckle, a prosthetic joint, a tympanostomy tube, a tracheostomy tube, a voice prosthetic, a penile prosthetic, an artificial urinary sphincter, a synthetic pubovaginal sling, a surgical suture, a bone anchor, a bone screw, an intraocular lens, a contact lens, an intrauterine device, an aortofemoral graft, a vascular graft, a needle, a Luer-Lok connector, a needleless connector or a surgical instrument.

21. The composition of claim 1 wherein said device is a central venous catheter, intravascular catheter, urinary catheter, Hickman catheter, peritoneal dialysis catheter, endrotracheal catheter, or wherein the device is a mechanical heart valve, a cardiac pacemaker, an arteriovenous shunt, a schleral buckle, a prosthetic joint, a tympanostomy tube, a tracheostomy tube, a voice prosthetic, a penile prosthetic, an artificial urinary sphincter, a synthetic pubovaginal sling, a surgical suture, a bone anchor, a bone screw, an intraocular lens, a contact lens, an intrauterine device, an aortofemoral graft, a vascular graft, a needle, a Luer-Lok connector, a needleless connector or a surgical instrument.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2017
From: BURGESS, JAMES GRANT; HALL, MICHAEL JOHN; NIJLAND, REINDERT
To: UNIVERSITY OF NEWCASTLE UPON TYNE
Reel/Frame 043255/0573 →
Priority Claims (1)
GB 1002396.8 · Feb 12, 2010 · national
Continuity (2)
Division 13578228
Related Publication 20170333601A1 · Nov 23, 2017
Cited By (1)
US 12,544,336